Pulmonary hypertension (PH) is a complex and progressive condition characterized by elevated pressures in the pulmonary arteries. Understanding its pathophysiology, diagnosis, and management is crucial for healthcare professionals.
PH originates from diverse etiologies leading to remodeling of the pulmonary vasculature, resulting in increased pulmonary vascular resistance and pulmonary arterial pressure. This ultimately causes right ventricular hypertrophy and heart failure.
Diagnosis of PH can be challenging due to its nonspecific symptoms. Initial diagnosis involves echocardiography, followed by right heart catheterization for confirmation. Additionally, various other tests like pulmonary function tests, chest radiography, and computed tomography can aid in identifying the underlying causes.
PH is classified into five groups based on etiology: Pulmonary arterial hypertension (PAH), PH due to left heart disease, PH due to lung diseases and/or hypoxia, Chronic thromboembolic PH (CTEPH), and PH with unclear multifactorial mechanisms. Each group requires a different treatment approach.
Treatment of PH is multifaceted and depends on the underlying cause. General measures include oxygen therapy, diuretics, and anticoagulation. Specific therapies for PAH include endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin analogues. In cases of CTEPH, pulmonary endarterectomy or balloon pulmonary angioplasty may be considered.
The prognosis of PH is generally poor, with survival rates varying greatly depending on the underlying cause. However, early diagnosis and appropriate management can significantly improve patient outcomes.
As healthcare professionals, it is essential to understand the complexities of PH to ensure accurate diagnosis and effective treatment. Continued research and advancements in targeted therapies hold promise for improved prognosis and quality of life for patients with PH.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation